CADTH's Drug Expert Committee has recommended the listing of botulinum toxin type A (Botox) and mirabegron (Myrbetriq) for patients with overactive bladder.

Botox has been recommended for the treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of anticholinergic medication, so long as patients have had an adequate trial with at least two other pharmacologic treatments.

Myrbetriq has been recommended for the treatment of overactive bladder with symptoms of urgency, urgency incontinence, and urinary frequency in patients who are intolerant or have had an inadequate response to an adequate trial of an anti-cholinergic therapy.